These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 25700837)

  • 1. Opportunistic yeast pathogens: reservoirs, virulence mechanisms, and therapeutic strategies.
    Polvi EJ; Li X; O'Meara TR; Leach MD; Cowen LE
    Cell Mol Life Sci; 2015 Jun; 72(12):2261-87. PubMed ID: 25700837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifungal drug resistance: evolution, mechanisms and impact.
    Revie NM; Iyer KR; Robbins N; Cowen LE
    Curr Opin Microbiol; 2018 Oct; 45():70-76. PubMed ID: 29547801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.
    Pfaller MA; Diekema DJ
    J Clin Microbiol; 2004 Oct; 42(10):4419-31. PubMed ID: 15472288
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting Stress Response Pathways with Alternative Strategies as a Novel Antifungal Approach.
    Ruhil S; Kumar V; Balhara M; Malik M; Chhillar AK
    Mini Rev Med Chem; 2021; 21(16):2337-2346. PubMed ID: 33749563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uncommon opportunistic fungi: new nosocomial threats.
    Groll AH; Walsh TJ
    Clin Microbiol Infect; 2001; 7 Suppl 2():8-24. PubMed ID: 11525222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing epidemiology of systemic fungal infections.
    Richardson M; Lass-Flörl C
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():5-24. PubMed ID: 18430126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virulence Attributes and Antifungal Susceptibility Profile of Opportunistic Fungi Isolated from Ophthalmic Infections.
    Sav H; Ozdemir HG; Altınbas R; Kiraz N; Ilkit M; Seyedmousavi S
    Mycopathologia; 2016 Oct; 181(9-10):653-61. PubMed ID: 27193295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting virulence: a new paradigm for antifungals.
    Gauwerky K; Borelli C; Korting HC
    Drug Discov Today; 2009 Feb; 14(3-4):214-22. PubMed ID: 19152839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress and prospects for targeting Hsp90 to treat fungal infections.
    Veri A; Cowen LE
    Parasitology; 2014 Aug; 141(9):1127-37. PubMed ID: 24560124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungals discovery: an insight into new strategies to combat antifungal resistance.
    Fuentefria AM; Pippi B; Dalla Lana DF; Donato KK; de Andrade SF
    Lett Appl Microbiol; 2018 Jan; 66(1):2-13. PubMed ID: 29112282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal Innate Immunity: A Perspective from the Last 10 Years.
    Salazar F; Brown GD
    J Innate Immun; 2018; 10(5-6):373-397. PubMed ID: 29768268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness.
    Anderson JB
    Nat Rev Microbiol; 2005 Jul; 3(7):547-56. PubMed ID: 15953931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fun(gi)omics: Advanced and Diverse Technologies to Explore Emerging Fungal Pathogens and Define Mechanisms of Antifungal Resistance.
    Ball B; Langille M; Geddes-McAlister J
    mBio; 2020 Oct; 11(5):. PubMed ID: 33024032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory circuitry governing fungal development, drug resistance, and disease.
    Shapiro RS; Robbins N; Cowen LE
    Microbiol Mol Biol Rev; 2011 Jun; 75(2):213-67. PubMed ID: 21646428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Mechanistic Targets of Antifungal Agents: An Overview.
    Mazu TK; Bricker BA; Flores-Rozas H; Ablordeppey SY
    Mini Rev Med Chem; 2016; 16(7):555-78. PubMed ID: 26776224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hidden killers: persistence of opportunistic fungal pathogens in the human host.
    d'Enfert C
    Curr Opin Microbiol; 2009 Aug; 12(4):358-64. PubMed ID: 19541532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combatting the evolution of antifungal resistance in Cryptococcus neoformans.
    Bermas A; Geddes-McAlister J
    Mol Microbiol; 2020 Nov; 114(5):721-734. PubMed ID: 32697029
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Tonui J; Mureithi M; Jaoko W; Bii C
    Pan Afr Med J; 2021; 38():227. PubMed ID: 34046132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging and less common fungal pathogens.
    Fleming RV; Walsh TJ; Anaissie EJ
    Infect Dis Clin North Am; 2002 Dec; 16(4):915-33, vi-vii. PubMed ID: 12512187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
    Lass-Flörl C; Mayr A; Perkhofer S; Hinterberger G; Hausdorfer J; Speth C; Fille M
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3637-41. PubMed ID: 18694949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.